Details of the Drug
General Information of Drug (ID: DMKB2P8)
Drug Name |
2-methylbut-3-yn-2-yl 4-methoxybenzoate
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
2-methylbut-3-yn-2-yl 4-methoxybenzoate; 294619-87-7; 1,1-dimethyl-2-propyn-1-yl 4-methoxybenzoate; ZERO/003209; AC1LE8OG; ARONIS020757; CHEMBL244918; ZINC96414; BDBM23726; KS-00004CEK; MolPort-001-510-482; BBL014263; STK001780; AKOS000487782; MCULE-8443375339; ST036671; 1,1-dimethylprop-2-ynyl 4-methoxybenzoate; BB0275130; 1,1-dimethyl-2-propynyl 4-methoxybenzoate; H2604; EU-0085447; SR-01000525786; AG-205/12908103; SR-01000525786-1; 1,1-dimethylprop-2-yn-1-yl 4-methoxybenzoate, 10; 4-Methoxybenzoic acid 1,1-dimethyl-2-propynyl es
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 218.25 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 2.5 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 5 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 0 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 3 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||